
Oncology NEWS International
- Oncology NEWS International Vol 10 No 7
- Volume 10
- Issue 7
NCI Launches Randomized Trial of Shark Cartilage in NSCLC
BETHESDA, Md-Enrollment has begun in a trial of Neovastat (Aeterna Laboratories), also known as AE-941, to test the Canadian-produced shark cartilage extract in patients with unresectable stages IIIA and IIIB non-small-cell lung cancer (NSCLC) who are undergoing induction chemotherapy and radiation therapy.
BETHESDA, MdEnrollment has begun in a trial of Neovastat (Aeterna Laboratories), also known as AE-941, to test the Canadian-produced shark cartilage extract in patients with unresectable stages IIIA and IIIB non-small-cell lung cancer (NSCLC) who are undergoing induction chemotherapy and radiation therapy.
The randomized, double-blind, placebo-controlled study, supported by the National Cancer Institute, anticipates enrolling 756 patients within the next 3 years at more than 50 sites in the United States and Canada.
Articles in this issue
almost 25 years ago
NCI to Expand Its Support for Trials of STI-571almost 25 years ago
Patients and Physicians Differ on Chemotherapy Expectationsalmost 25 years ago
Concurrent Chemoradiotherapy Helps Preserve Larynxalmost 25 years ago
Once-Daily, Rapid-Onset Morphine Offers Alternative for Those in Severe Painalmost 25 years ago
FDA Issues New Safeguards for Children in Clinical Trialsalmost 25 years ago
Leukemia Society Offers Patient Information on Use of STI-571Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.


















































